Show simple item record

dc.contributor.editorVermehren, Charlotte
dc.contributor.editorWestergaard, Niels
dc.date.accessioned2023-02-20T16:46:28Z
dc.date.available2023-02-20T16:46:28Z
dc.date.issued2022
dc.identifierONIX_20230220_9783036551623_83
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/97480
dc.description.abstractPolypharmacy is a necessary and important aspect of drug treatment; however, it becomes a challenge when the medication risks outweigh the benefits for an individual patient. Drug–drug interactions and the introduction of prescribing cascades are common features of polypharmacy, which can lead to ineffectiveness and increased risk of adverse drug reactions (ADR). Genes encoding CYP450 isozymes and other drug-related biomarkers have attracted considerable attention as targets for pharmacogenetic (PGx) testing due to their impact on drug metabolism and response. This Special Issue is devoted to explore the status and initiatives taken to circumvent ineffectiveness and to improve medication safety for polypharmacy patients. Specific areas include drug–drug interactions and consequences thereof in therapeutic management, including PK- and PD-profiling; the application of PGx-based guidance and/or decision tools for drug–gene and drug–drug gene interactions; medication reviews; development and application of deprescribing tools; and drivers and barriers to overcome for successful implementation in the healthcare system.
dc.languageEnglish
dc.subject.classificationbic Book Industry Communication::M Medicine
dc.subject.classificationbic Book Industry Communication::K Economics, finance, business & management::KN Industry & industrial studies::KND Manufacturing industries::KNDP Pharmaceutical industries
dc.subject.otheracute kidney injury
dc.subject.otherearly biomarker
dc.subject.otherplasma neutrophil gelatinase-associated lipocalin
dc.subject.othersoluble urokinase plasminogen activator receptor
dc.subject.othermedication optimization
dc.subject.otherolder patients
dc.subject.otheremergency department
dc.subject.othermultimorbidity
dc.subject.otherpolypharmacy
dc.subject.otherpotentially inappropriate medication use
dc.subject.otherolder adults
dc.subject.otherprevalence
dc.subject.otherdeterminants
dc.subject.otherchronic
dc.subject.otheroutpatient
dc.subject.other2019 Beers criteria
dc.subject.otherEthiopia
dc.subject.otherpharmacogenomics
dc.subject.otherpersons with diabetes
dc.subject.otherdrug–drug interactions
dc.subject.otherdrug–gene interactions
dc.subject.othercytochrome P450
dc.subject.otherSLCO1B1
dc.subject.otherdrug interaction checkers
dc.subject.otheradverse drug reactions
dc.subject.otherpharmacogenetics
dc.subject.otherpersonalized medicine
dc.subject.otherphenprocoumon
dc.subject.otherDOACs
dc.subject.otherbleeding
dc.subject.otherthromboembolism
dc.subject.otherHLA
dc.subject.otherdrug hypersensitivity
dc.subject.otherabacavir
dc.subject.otherallopurinol
dc.subject.otherflucloxacillin
dc.subject.otherantiepileptic drugs
dc.subject.othercost-effectiveness
dc.subject.othershared medication record
dc.subject.othermedication reconciliation
dc.subject.otherdrug information service
dc.subject.otherhospital pharmacy service
dc.subject.otherelectronic prescribing
dc.subject.otherelectronic medical record
dc.subject.otherclinical pharmacist
dc.subject.otherCYP2D6
dc.subject.otherCYP2D7P
dc.subject.otherCYP2D8P
dc.subject.othercopy number variation
dc.subject.otherCNV
dc.subject.othergenotyping
dc.subject.other5’nuclease assay
dc.subject.otherHRM
dc.subject.otherhigh resolution melting
dc.subject.otherdrug metabolization
dc.subject.otherextracellular vesicles
dc.subject.otherexosomes
dc.subject.othermicrovesicles
dc.subject.otherpharmacogene expression
dc.subject.othermedication review
dc.subject.otherdeprescriptions
dc.subject.otherquality of life
dc.subject.otheraged
dc.subject.other80 and over
dc.subject.othernursing homes
dc.subject.otherdeprescribing
dc.subject.othermedication-based risk score
dc.subject.otherhealth outcomes
dc.subject.othercytochromes
dc.subject.otherCYP1A2
dc.subject.otheradverse drug reaction
dc.subject.otherantipsychotics
dc.subject.otherolanzapine
dc.subject.otherclozapine
dc.subject.otherloxapine
dc.subject.otherchildren
dc.subject.otheryouth
dc.subject.otherdigital decision-support
dc.subject.otherhealth services research
dc.subject.othergeneral practice
dc.subject.otherprocess evaluation
dc.subject.otherantidepressants
dc.subject.otherutility
dc.subject.otherpopulation-based
dc.subject.otherappropriateness
dc.subject.othermedication adherence
dc.subject.otherdigital health
dc.titleClinical Utility of Applying PGx and Deprescribing-Based Decision Support in Polypharmacy
dc.title.alternativeFuture Perspectives
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-5161-6
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036551623
oapen.relation.isbn9783036551616
oapen.pages224
oapen.place.publicationBasel


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/